The 2-year overall survival rate was 32.5%.
Researchers found that, in 18% of recurrences, the new tumor was molecularly unrelated to the original tumor.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Waldenström macroglobulinemia.
Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.